FINAL FINDINGS OF SCIENTIFIC MISCONDUCT NIH GUIDE, Volume 22, Number 23, June 25, 1993 P.T. 34 Keywords: Ethics/Values in Science & Technol National Institutes of Health The Office of Research Integrity (ORI) has begun publication of final findings of scientific misconduct involving Public Health Service research. This information will assist in correcting the scientific literature, will serve an educational and deterrent purpose, and will assist institutional officials in making informed decisions affecting their institution. Fourteen cases that have been closed since the ORI was established on May 29, 1992 have been published in the Federal Register (58FR33830, June 21, 1993). To ensure that officials of institutions receiving Public Health Service research funds, or applying for such funds, are made aware of these findings of scientific misconduct, this information is also being published in the NIH Guide for Grants and Contracts. Future cases will be published in the Federal Register and the NIH Guide individually as cases are closed. Final findings of scientific misconduct have been made in the following cases: James H. Freisheim, Ph.D., Medical College of Ohio. An inquiry and an investigation conducted by the University found that Dr. Freisheim had submitted a research grant application to the National Institutes of Health which contained substantial portions plagiarized from another scientist\"s grant application. Dr. Freisheim had served as an assigned reviewer of the other scientist\"s application when it was reviewed about two years earlier by an NIH Study Section. During the inquiry, Dr. Freisheim produced a handwritten draft of the plagiarized material that he claimed he had written before the other scientist had submitted his grant application, and that therefore the other scientist had plagiarized Dr. Freisheim\"s work. The investigation reviewed the handwritten draft and concluded that it had been written much later than purported by Dr. Freisheim, possibly during the inquiry to establish the basis for his defense. The investigation also concluded that Dr. Freisheim had plagiarized material for two post-doctoral fellowship applications to the NIH. The ORI concurred in the University\"s findings, and Dr. Freisheim has been debarred from receiving Federal grant or contract funds for a period of three years beginning May 5, 1993. He has also been required, for a ten year period beginning May 5, 1993, to certify that future applications for research support submitted to the PHS are his own work, and he has been prohibited from serving on PHS Advisory Committees or review groups for the same period. Judy Guffee, University of Miami. An investigation conducted by the University found that Ms. Guffee had fabricated data in a research project that was supported by a grant from the National Institutes of Health. Ms. Guffee admitted to falsifying the labeling of solutions alleged to contain polyclonal antiserum, when in fact she filled the tubes with fetal calf serum. The investigation concluded that this was done to hide the fact that the animal preparation used to generate the polyclonal antiserum had died before large quantities of antiserum could be produced. Records indicating collection of large quantities of serum from the animal over a two-year period were also fabricated. ORI concurred in the University\"s finding and has required, for a five year period beginning January 7, 1993, that she and the institution submit a certification with any PHS fellowship or grant application or contract proposal prepared by her attesting to the accuracy of the statements therein. Raymond J. Ivatt, Ph.D., Cetus Corporation, Emeryville, CA. An investigation conducted by the Corporation found that Dr. Ivatt falsified progress reports in a research project grant supported by the National Institutes of Health. Dr. Ivatt reported progress from an earlier budget period, claiming that the work had been done during the period for which current funds were awarded. The ORI concurred with the Corporation\"s findings and has required that applications for PHS research support and reports of PHS sponsored research involving Dr. Ivatt be reviewed and certified by the sponsoring institution for the reliability and accuracy of the application, contract proposal, or report. Dr. Ivatt is also prohibited from serving on PHS Advisory Committees, boards, or peer review groups. These actions are effective for 3 years beginning February 28, 1993. Mark M. Kowalski, M.D., Ph.D., Dana Farber Cancer Institute and Harvard University. An investigation conducted by the Institute found that Dr. Kowalski had plagiarized a complete grant application and submitted it to the National Institutes of Health. He copied the previously funded grant application of his former mentor and submitted it as his own work. The ORI concurred in the Institute\"s finding and has required that, for any PHS application, proposal or report prepared by Dr. Kowalski, a signed affirmation be submitted that all material is entirely his own work or accurately attributed to others. In addition, he has been prohibited by the ORI from serving on Public Health Service Advisory Committees, Boards, or review groups. These actions became effective January 6, 1993 for a three year period. Paul F. Langlois, D.Sc.N., Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases. An inquiry by the NIAID and a subsequent investigation conducted by the former Office of Scientific Integrity at the National Institutes of Health concluded that Dr. Langlois, a former post-doctoral fellow in the laboratory, had falsified and fabricated data in immunological research. Dr. Langlois presented to his supervisor computer printouts and graphs for which primary data did not exist. Dr. Langlois admitted to fabricating the data. Dr. Langlois also admitted to manipulating the reagents used by other laboratory personnel in efforts to replicate his findings, spiking them with radioactive antibody to show positive results. The Public Health Service recommended that Dr. Langlois be debarred from receiving Federal grant or contract funds for a three year period, and that he be prohibited from serving on PHS Advisory Committees, Boards, or peer review groups for three years. Dr. Langlois appealed the term of the proposed debarment to a Research Integrity Adjudications Panel of the HHS Departmental Appeals Board, but the Panel upheld the PHS recommendation. Accordingly, Dr. Langlois has been debarred for three years beginning May 12, 1993, and is prohibited from serving on PHS Advisory Committees, Boards, or peer review groups for the same period. The fabricated and falsified data was never published in the scientific literature. Tian-Shing Lee, M.D., Joslin Diabetes Center, Harvard Medical School. An investigation conducted by Harvard found that Dr. Lee, a former post-doctoral fellow at the Joslin Diabetes Center, fabricated and falsified data in research on diabetes supported by the National Eye Institute. Primary data was missing for almost half of the figures and tables in a series of published papers and manuscripts prepared by Dr. Lee. Many instances of data fabrication and falsification were found, including presenting data for cell counts that were never performed, indicating that multiple data points were determined when in fact only a single data point was obtained, eliminating the highest or lowest values in sets of experimental readings, alteration or transposition of data to achieve a desired experimental result, and misrepresentation of the time intervals at which data was collected. The Office of Research Integrity concurred in the University\"s findings. Dr. Lee has been debarred from receiving Federal grants or contracts and is prohibited from serving on Public Health Service Advisory Committees, Boards, or peer review groups for a five year period beginning April 18, 1993. Harvard University notified the four scientific journals which had published papers containing data fabricated or falsified by Dr. Lee that the papers should be retracted. These papers are: \"Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose level in retinal capillary endothelial cell\" Journal of Clinical Investigation, 83: 90-94, 1989, \"Endothelin stimulates a sustained 1,2-diacylglycerool increase and protein kinase C activation in bovine aortic smooth muscle cells\" Biochemical and Biophysical Research Communications, 162: 381-386, 1989: \"Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications\" Proceedings of the National Academy of Sciences, 86: 5141-5145, 1989, and \"Characterization of endothelin receptors and effects of endothelin on diacylglycerol and protein kinase C in retinal capillary pericytes\" Diabetes, 38: 1642-1646, 1989. Anthony A. Paparo, Ph.D., Southern Illinois University. An investigation conducted by the University found that Dr. Paparo had falsified data in publications citing support by a grant from the National Institutes of Health. He used the same micrograph in two papers, while stating that the micrographs had been obtained from two different biological species of mussel. Multiple instances were found of other such falsification of micrographs and radioisotope data in published scientific articles which were not supported by the PHS. The ORI concurred in the University\"s finding and has prohibited Dr. Paparo from serving on Public Health Service Advisory Committees, Boards, or review groups for a three year period. He has also been debarred from receiving Federal grants or contracts for three years, effective April 5, 1993. The two published papers which cited PHS support are: \"The effect of STH and 6-OH-DOPA on the SEM of the branchial nerve and visceral ganglion of the bivalve Elliptio companata as it relates to ciliary activity\" Comparative Biochemistry and Physiology, 51: 169-173, 1975, \"The effect of STH on the SEM and frequency response of the branchial nerve in Mytilus Edulis as it relates to ciliary activity\" Comparative Biochemistry and Physiology, 51: 165-168, 1975. The University has notified the editor of this journal, and the editors of other journals in which Dr. Paparo published, about the problems identified in the investigation. Leo A. Paquette, Ph.D., Ohio State University. An investigation conducted by the University found that Dr. Paquette had submitted a grant application to the National Institutes of Health in which sections of the research design were plagiarized from an unfunded grant application written by another scientist. Dr. Paquette had received the other scientist\"s application in confidence as a peer reviewer for the NIH. Dr. Paquette claimed that inclusion of the other scientist\"s text was inadvertent, he said that he had given the other scientist\"s application to a postdoctoral fellow, whom Dr. Paquette refused to name, for an educational exercise, and that text had somehow been inadvertently used in his own application. The ORI concurred in the University\"s finding of misconduct. Dr. Paquette stated that he was accepting full responsibility for this occurrence. The ORI has required institutional certification of proper attribution in any future grant proposals to the PHS from Dr. Paquette and has prohibited him from serving on Public Health Service Advisory Committees, Boards, or review groups. These actions are effective for a ten year period beginning December 31, 1992. Roger Poisson, M.D., St. Luc Hospital, Montreal, Canada. An investigation conducted by the Division of Research Investigations of the ORI found that Dr. Poisson had fabricated and falsified research data in clinical trials supported by a cooperative agreement from the National Institutes of Health. Dr. Poisson fabricated or falsified data related to laboratory tests and dates of procedures in 115 separate instances dating from 1977 through 1990. The ORI has prohibited Dr. Poisson from serving on Public Health Advisory Committees, Boards, or review groups for an eight year period. Dr. Poisson has also been debarred from receiving Federal grants or contracts for an eight year period. These actions became effective March 30, 1993. The National Cancer Institute cooperative clinical trials group which sponsored the clinical trials, the National Surgical Adjuvant Breast and Bowel Project (NSABP), plans to publish corrected analyses of affected studies. Sheela Ramasubban, University of Houston. An investigation conducted by the University found that Ms. Ramasubban, a former Master\"s degree student in the Department of Biochemical and Biophysical Sciences, falsified and fabricated data in research on the biochemical basis of rhythmic behaviors, supported by a grant from the National Institute of Mental Health. Ms. Ramasubban admitted to the investigation committee that she had altered the data in her notebooks and fabricated data in a number of instances. A hearing conducted by the University upheld the investigative findings of scientific misconduct. The ORI concurred in the University\"s findings, and Ms. Ramasubban has been debarred from eligibility for and involvement in Federal grants and contracts for a three-year period beginning May 18, 1993. Ms. Ramasubban has also been required to provide special certification for the accuracy and reliability of any PHS research fellowship application or contract proposal for a three-year period beginning December 1, 1992. The falsified and fabricated data did not appear in any scientific publications. Mitchell H. Rosner, National Cancer Institute. An inquiry conducted by the National Cancer Institute (NCI) and a subsequent investigation conducted by the Office of Research Integrity (ORI) found that Mr. Rosner, a Howard Hughes Medical Institute-NIH Scholar in residence at the NCI, falsified research on embryonic development in mice. Mr. Rosner diluted control samples that were injected into mouse germ cells so that the control material would have a different effect on embryonic development from the experimental samples. The results of these experiments were published in the journal Cell, demonstrating that a certain regulatory protein was essential for normal embryonic development. In later efforts by Mr. Rosner\"s collaborators and supervisors to replicate the original findings, Mr. Rosner again diluted control samples before their injection into mouse germ cells, in order to obtain the previous results. Mr. Rosner admitted to these acts of falsification, and has signed an agreement with the Office of Research Integrity that he will exclude himself for a five year period beginning April 1, 1992 from any Federal grants or contracts, and from serving on any Public Health Service advisory committees. The publication containing the falsified results (Cell, 64: 1103-1110, 1991) has been retracted by a notice in Cell, 69: 724, 1992. Craig T. Shelley, M.D., University of Tennessee at Memphis. Dr. Shelley was a neurosurgical resident at the University of Tennessee and a former resident fellow at the National Institute of Neurological Disorders and Stroke, National Institutes of Health. The University of Tennessee conducted an inquiry into allegations that Dr. Shelley had fabricated and falsified data in research on brain tumors. A followup investigation by the former Office of Scientific Integrity (OSI) confirmed that Dr. Shelley had altered an autoradiographic slide so that data from a single tumor were made to look as though several tumors were tested. Dr. Shelley admitted to falsifying the slide and falsely reporting the source of a clonal cell line. He also admitted that he had created other data by improperly selecting tissues so the results presented would support his hypothesis. The Office of Research Integrity concurred in the University\"s findings and the OSI findings, and has prohibited Dr. Shelley from serving on Public Health Service advisory or review committees for a three year period beginning October 10, 1992. Dr. Shelley was also debarred from receiving Federal grants or contracts for a three year period, beginning April 7, 1993. The fabricated and falsified data did not appear in any publications. Michael A. Sherer, M.D., Addiction Research Center (ARC), National Institute on Drug Abuse. An investigation conducted by the former Office of Scientific Integrity found that Dr. Sherer had falsified the nature, quality and methodology for data collection and behavioral ratings as well as the descriptions in two publications arising from research at the ARC in 1989. The ORI has required institutional certification of the reliability of the proposed research and the underlying data for any future PHS grant applications and publications submitted by Dr. Sherer, and notification of the advisory council of the funding agency reviewing such applications about the finding of scientific misconduct. Dr. Sherer has also been prohibited from serving on Public Health Service Advisory Committees, Boards, or review groups. These actions are effective for a three year period, beginning November 9, 1992. Dr. Sherer has also been required to submit a letter of retraction for the article \"Suspiciousness induced by four-hour intravenous infusions of cocaine\", Archives of General Psychiatry, 45: 673-677, 1988, and a letter of correction for the article \"Intravenous cocaine: Psychiatric effects\", Biological Psychiatry, 24: 865-885, 1988. Raphael B. Stricker, M.D., University of California at San Francisco. An investigation conducted by the University found that Dr. Stricker falsified data for a manuscript and a PHS-supported publication reporting research on AIDS. In the manuscript, Dr. Stricker selectively suppressed data that did not support his hypothesis, and reported consistently positive data whereas only one of four experiments had produced positive results. In the publication, Dr. Stricker reported that an antibody was found in 29 of 30 homosexuals, but not found in non-homosexuals. However, Dr. Stricker\"s control data, which he suppressed, showed the antibody in 33 of 65 non- homosexuals. The falsified data was used as the basis for a grant application to the National Institutes of Health. The ORI concurred in the University\"s finding. Dr. Stricker executed a Voluntary Exclusion and Settlement Agreement in which he has agreed not to apply for Federal grant or contract funds and will not serve on PHS advisory committees, boards or peer review groups for a three year period beginning April 1, 1993. The publication \"Target platelet antigen in homosexual men with immune thrombocytopenia\" in the New England Journal of Medicine, 313: 1315-1380, 1985 has been retracted (New England Journal of Medicine, 325: 1487,1991). INQUIRIES The Office of Research Integrity will continue to publish findings of scientific misconduct as further cases are closed. For further information, contact: Director, Division of Research Investigations Office of Research Integrity Telephone: (301) 443-5330
